Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2027
Employees
45

Recommended

Frontier AI labs face a three-pronged set of challenges.

Malik Ahmed Khan, CFA | 18 October 2026

We think it is a sign that the firm is finally moving out of its comfort zone to find places to put capital to work.

Greggory Warren, CFA | 18 October 2026

The market may be overlooking this share’s long-term value.

Esther Holloway | 18 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,975.70	35.30	0.39%
CAC 40	7,868.05	88.65	-1.11%
DAX 40	25,319.77	302.84	-1.18%
Dow JONES (US)	52,015.29	12.88	0.02%
FTSE 100	10,764.69	117.21	-1.08%
HKSE	24,186.83	124.11	0.52%
NASDAQ	26,442.73	302.69	1.16%
Nikkei 225	64,916.70	407.59	-0.62%
NZX 50 Index	13,652.07	101.66	-0.74%
S&P 500	7,699.62	40.18	0.52%
S&P/ASX 200	8,845.70	39.00	0.44%
SSE Composite Index	3,716.28	8.81	0.24%